Bleeding News and Research

RSS

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

16 Nov 2008

A new method to control bleeding in hemophilia

Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets.

13 Nov 2008

Adalimumab therapy may reduce health-care costs for Crohn's disease patients

Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD).

12 Nov 2008

Catheter ablation works better than drugs for heart rhythm disorder

Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, a major international study has found.

11 Nov 2008

Cell-coated stent as effective as drug-coated ones

A stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents in keeping arteries open in coronary heart disease patients, according to two research studies presented at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Large trial on low-dose aspirin in diabetics

Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.

11 Nov 2008

Tailored anti-clotting medications reduce adverse effects after percutaneous coronary intervention

Individually tailored anti-clotting medication dosing significantly cut the rate of adverse events after non-emergent percutaneous coronary intervention (PCI) with stenting, researchers reported at the American Heart Association's Scientific Sessions 2008. Results of the Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Stent Thrombosis study were presented as a late-breaking clinical trial.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Researchers unravel mysteries of brain aneurysms

Yale researchers have taken the first critical steps in unraveling the mysteries of brain aneurysms, the often fatal rupturing of blood vessels that afflicts 500,000 people worldwide each year and nearly killed Vice President-elect Joseph Biden two decades ago.

10 Nov 2008

Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes

Low-dose aspirin as primary prevention did not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type 2 diabetes, according to a new study in JAMA.

10 Nov 2008

10 symptoms that should never be ignored

Not every ache and pain merits a quick trip to the doctor -- but some do.

6 Nov 2008

New clinical study will help doctors assess abnormal bleeding

How do you know if you bleed normally? Scientists at The Rockefeller University Hospital's Center for Clinical and Translational Science (CCTS) aim to answer that question more definitively with the launch of an assessment tool designed to help physicians and researchers more accurately determine what is inside and outside the normal range of bleeding symptoms.

3 Nov 2008

Tiny hearts may have big problems with complementary medicine

Giving supplement such as herbs, vitamins, and other natural health products to children taking Warfarin for congenital heart defects could increase their risk of clots, bleeding, and other complications, nurse practitioner Mary Bauman and Dr. Patti Massicotte told the 2008 Canadian Cardiovascular Congress, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

28 Oct 2008

FDA warns Bayer HealthCare on over-the-counter aspirin product

The U.S. Food and Drug Administration today sent Warning Letters to Bayer HealthCare concerning two unlawful, over-the-counter (OTC) aspirin products - Bayer Women's Low Dose Aspirin + Calcium (Bayer Women's) and Bayer Aspirin with Heart Advantage (Bayer Heart Advantage).

28 Oct 2008

Improved communication about medications reduces complications among patients using common blood thinner

Patients who report receiving written and verbal instructions on the proper way to take the blood thinner warfarin are significantly less likely to suffer the serious gastrointestinal and brain bleeding problems that are associated with misuse of the drug, according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2008

FDA approves lung valve to control some air leaks post-surgery

The U.S. Food and Drug Administration has approved an implantable and removable valve system designed to control some air leaks in the lungs that persist after certain kinds of lung surgery.

26 Oct 2008

Leukaemia drug may reverse multiple sclerosis brain damage

Scientists in Britain say a drug which was developed to treat leukaemia may also be a powerful new weapon against multiple sclerosis (MS).

23 Oct 2008

Medtronic launches new device to improve minimally-invasive treatment of thoracic aortic aneurysms

Extending an unmatched record of innovation in the field of endovascular aortic repair, Medtronic, Inc., today announced the U.S. market launch of the Talent Thoracic Stent Graft on the Xcelerant Delivery System, which makes minimally-invasive treatment of thoracic aortic aneurysms easier to perform.

22 Oct 2008

FDA approves new labeling for psoriasis drug Raptiva

The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.

19 Oct 2008

St. Jude Medical gets U.S. and European approval of Angio-Seal Evolution Vascular Closure Device

St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

14 Oct 2008